New Paper on INF vs Covid published in Nature28 Apr 2022 22:46
https://www.nature.com/articles/s41598-022-10763-2
Quite a bit in here, but it's basically a big flashing advertisement for SNG001
The money shot:
"Given the steady evolution of new SARS-CoV-2 variants through 2021 and continued significant resistance to vaccination among a sizable minority of people with access to vaccines, the pandemic has continued to result in high levels of morbidity and mortality in many areas of the world, fueling an ongoing need for therapeutics to treat COVID-19. Our results demonstrating marked reduction in SARS-CoV-2 replication in AEC cultures treated with recombinant IFNß1 or IFN?2 provides further mechanistic evidence to support the possible use of inhaled interferon as a possible treatment option if initiated early enough during COVID-19. A recent randomized, double-blind, placebo-controlled, phase 2 trial of inhaled nebulized interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection demonstrated that patients who received SNG001 early in their disease course had greater odds of improvement and recovered more rapidly from SARS-CoV-2 infection than patients who received placebo, providing a strong rationale for further trials of this agent61."